XML 137 R104.htm IDEA: XBRL DOCUMENT v3.10.0.1

Equity (Share-based Payments to Employees, Non-marketable Options) (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2018 shares
Non-marketable options [Member] | Officers and senior employees [Member] | August 6, 2014 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	3,993
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, to 450 ICL officers and senior employees in Israel and overseas.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. In case of on the exercise date the closing price of an ordinary share is higher than twice the exercise price (the “Share Value Cap”), the number of the exercised shares will be reduced so that the product of the exercised shares actually issued to an offeree multiplied by the share closing price will equal to the product of the number of exercised options multiplied by the Share Value Cap.
Vesting conditions	3 equal tranches: (1) One third on December 1, 2016 (2) One third on December 1, 2017 (3) One third on December 1, 2018
Expiration date	Two years from the vesting date.
Non-marketable options [Member] | Officers and senior employees [Member] | May 12, 2015 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	6,729
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, to 550 ICL officers and senior employees in Israel and overseas.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	The first and second tranches is at the end of 36 months after the grant date for the third tranche is at the end of 48 months after the grant date.
Non-marketable options [Member] | Officers and senior employees [Member] | June 30, 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	3,035
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan, to 90 ICL officers and senior employees in Israel and overseas.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	June 30, 2023
Non-marketable options [Member] | Officers and senior employees [Member] | June 20, 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	6,868
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan to 498 ICL officers and senior employees in Israel and overseas.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	June 20, 2024
Non-marketable options [Member] | Officers and senior employees [Member] | March 6, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	5,554
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan (as amended) to 508 ICL officers and senior employees in Israel and overseas, ICL CEO and Chairman of the BOD.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	March 6, 2025
Non-marketable options [Member] | Former CEO [Member] | December 11, 2014 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	367
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. In case of on the exercise date the closing price of an ordinary share is higher than twice the exercise price (the “Share Value Cap”), the number of the exercised shares will be reduced so that the product of the exercised shares actually issued to an offeree multiplied by the share closing price will equal to the product of the number of exercised options multiplied by the Share Value Cap.
Vesting conditions	3 equal tranches: (1) One third on December 1, 2016 (2) One third on December 1, 2017 (3) One third on December 1, 2018
Expiration date	Two years from the vesting date.
Non-marketable options [Member] | Former CEO [Member] | June 29, 2015 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	530
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	The first and second tranches is at the end of 36 months after the grant date for the third tranche is at the end of 48 months after the grant date.
Non-marketable options [Member] | Former CEO [Member] | September 5, 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	625
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	June 30, 2023
Non-marketable options [Member] | Former CEO [Member] | February 14, 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	114
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	February 14, 2024
Non-marketable options [Member] | Chairman of the BOD [Member] | September 5, 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	186
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	June 30, 2023
Non-marketable options [Member] | Chairman of the BOD [Member] | August 2, 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	165
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	June 20, 2024
Non-marketable options [Member] | Chairman of the BOD [Member] | August 20, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	403
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan (as amended) to 508 ICL officers and senior employees in Israel and overseas, ICL CEO and Chairman of the BOD.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	August 20, 2025
Non-marketable options [Member] | Former chairman of the BOD [Member] | June 29, 2015 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	404
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	The first and second tranches is at the end of 36 months after the grant date for the third tranche is at the end of 48 months after the grant date.
Non-marketable options [Member] | CEO [Member] | May 14, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	385
Issuance's details	An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan (as amended) to 508 ICL officers and senior employees in Israel and overseas, ICL CEO and Chairman of the BOD.
Instrument terms	Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date
Expiration date	May 14, 2025
Restricted shares [Member] | Officers and senior employees [Member] | August 6, 2014 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	922
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan, to 450 ICL officers and senior employees in Israel and overseas.
Vesting conditions	3 equal tranches: (1) One third on December 1, 2016 (2) One third on December 1, 2017 (3) One third on December 1, 2018	[1]
Restricted shares [Member] | Officers and senior employees [Member] | May 12, 2015 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	1,194
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan, to 550 ICL officers and senior employees in Israel and overseas.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | Officers and senior employees [Member] | June 30, 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	990
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan, to 90 ICL officers and senior employees in Israel and overseas.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | Officers and senior employees [Member] | June 20, 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	2,211
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan, to 494 ICL officers and senior employees in Israel and overseas.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | Officers and senior employees [Member] | March 6, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	1,726
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan (as amended).
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | Former CEO [Member] | December 11, 2014 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	86
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan.
Vesting conditions	3 equal tranches: (1) One third on December 1, 2016 (2) One third on December 1, 2017 (3) One third on December 1, 2018	[1]
Restricted shares [Member] | Former CEO [Member] | June 29, 2015 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	90
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | Former CEO [Member] | September 5, 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	185
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | Former CEO [Member] | February 14, 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	38
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | ICLs Directors (excluding ICLs CEO) [Member] | February 26, 2015 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	99
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan, to 11 ICL Directors.
Vesting conditions	3 tranches: (1) 50% will vest August 28, 2015 (2) 25% will vest February 26, 2017 (3) 25% will vest February 26, 2018	[1]
Restricted shares [Member] | ICLs Directors (excluding ICLs CEO and Chairman of the BOD) [Member] | December 23, 2015 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	121
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan, to 8 ICL Directors.
Vesting conditions	3 equal tranches: (1) One third on December 23, 2016 (2) One third on December 23, 2017 (3) One third on December 23, 2018	[1]
Restricted shares [Member] | ICLs Directors (excluding ICLs CEO and Chairman of the BOD) [Member] | January 10, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	137
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan, to 7 ICL Directors.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | ICLs Directors (excluding ICLs CEO and Chairman of the BOD) [Member] | August 20, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	88
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan (as amended).
Vesting conditions	Acceleration at January 2019.	[1]
Restricted shares [Member] | ICLs Directors (excluding ICLs Chairman of the BOD) [Member] | January 3, 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	146
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan, to 8 ICL Directors. The value includes a reduction of 5% from the value of the equity compensation, pursuant to the decision of the directors in March 2016, to reduce their annual compensation for 2016 and 2017.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | Chairman of the BOD [Member] | September 5, 2016 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	55
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | Chairman of the BOD [Member] | August 2, 2017 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	53
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | Chairman of the BOD [Member] | August 20, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	47
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan (as amended).
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | Former chairman of the BOD [Member] | June 29, 2015 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	68
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan.
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
Restricted shares [Member] | CEO [Member] | May 14, 2018 [Member]
Disclosure of terms and conditions of share-based payment arrangement [Line Items]
Number of instruments (thousands)	121
Issuance's details	The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the date approval of the BOD and/or the date of the approval of the General Meeting where required).
Instrument terms	An issuance for no consideration, under the 2014 Equity Compensation Plan (as amended).
Vesting conditions	3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date	[1]
[1] The vesting date is subject to the employee entitled continuing to be employed by the Company and the directors continuing to serve in their positions on the vesting date, unless they ceased to hold office due to certain circumstances set forth in sections 231-232a and 233(2) of the Israeli Companies Law.

X

- References

No definition available.

+ Details

Name:	icl_NumberOfInstruments
Namespace Prefix:	icl_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The description of the maximum term of options granted for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2018-01-01
-Paragraph 45
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=2&date=2018-03-01&anchor=para_45_a&doctype=Standard
-URIDate 2018-03-16

+ Details

Name:	ifrs-full_DescriptionOfMaximumTermOfOptionsGrantedForSharebasedPaymentArrangement
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The description of the method of settlement (for example, whether in cash or equity) for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2018-01-01
-Paragraph 45
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=2&date=2018-03-01&anchor=para_45_a&doctype=Standard
-URIDate 2018-03-16

+ Details

Name:	ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2018-01-01
-Paragraph 45
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=2&date=2018-03-01&anchor=para_45_a&doctype=Standard
-URIDate 2018-03-16

+ Details

Name:	ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The description of a share-based payment arrangement that existed at any time during the reporting period. [Refer: Share-based payment arrangements [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 2
-IssueDate 2018-01-01
-Paragraph 45
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=2&date=2018-03-01&anchor=para_45_a&doctype=Standard
-URIDate 2018-03-16

+ Details

Name:	ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	ifrs-full_ClassesOfShareCapitalAxis=icl_NonmarketableOptionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_EmployeeFunctionAxis=icl_OfficersAndSeniorEmployeesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_August62014Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_May122015FMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_June302016Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_June202017Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_March62018Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_EmployeeFunctionAxis=icl_FormerCEOMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_December112014Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_June292015Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_September52016Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_February142017Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_EmployeeFunctionAxis=icl_ChairmanBODMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_August22017Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_August202018Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_EmployeeFunctionAxis=icl_FormerChairmanBODMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_EmployeeFunctionAxis=icl_CEOMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_May142018Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ClassesOfShareCapitalAxis=icl_RestrictedSharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_EmployeeFunctionAxis=icl_ICLDirectorsExcludingCEOMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_February262015Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_EmployeeFunctionAxis=icl_ICLDirectorsExcludingCEOAndChairmanBODMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_December232015Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_January102018Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_EmployeeFunctionAxis=icl_ICLDirectorsExcludingChairmanBODMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	icl_GrantDateAxis=icl_January32017Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: